With support from Bates White, pharmaceutical manufacturer Amgen Inc. recently settled litigation with Teva Pharmaceuticals USA Inc. concerning Teva’s challenge to the validity of Amgen’s patents for Neupogen. The client obtained a favorable outcome through an agreement that prevents Teva from introducing its infringing drug in the United States before November 2013.
Dr. Douglas Bernheim testified on behalf of Amgen in Amgen v. F. Hoffman-La Roche to advise the court considering whether to grant a permanent injunction against Roche’s sales and marketing of a product that infringes Amgen’s patents. The judge issued a court order that agreed with Dr. Bernheim’s conclusions and cited his testimony extensively.
For businesses competing in today’s rapidly evolving markets, intellectual property is a vital component of economic success. Many of Bates White’s clients invest heavily in innovation and in the development of intellectual property, and they often face challenging IP management issues throughout the life cycle of their products. We have extensive experience conducting economic analysis in IP negotiation and litigation, and our professionals are called upon to provide opinions as consulting and testifying experts. We take a hands-on approach to develop a deep understanding of the relevant industry, factual, and legal contexts of each matter, and we complement our in-house expertise through an extensive network of leading academics and industry experts.
Our expertise in intellectual property includes:
- Antitrust and IP
- Copyrights, trade secrets, and trademarks
Our economic analysis is complemented by our experience advising clients in diverse industries and technologies:
- New York, NY, May 3, 2011 – May 4, 2011
- Palo Alto, CA, April 13, 2010